Association of hospital construction with the development of healthcare associated environmental mold infections (HAEMI) in pediatric patients with leukemia

Pediatric Blood and Cancer

Volumn 61, Issue 2, 2014, Pages 276-280

  Pokala, Hanumantha R ^a   Leonard, David ^b   Cox, Jennifer ^c   Metcalf, Pat ^d   Mcclay, John ^e   Siegel, Jane ^e   Winick, Naomi ^e  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b CHILDREN S MEDICAL CENTER   (United States)

^c HUNTSVILLE HOSPITAL   (United States)

^d METHODIST DALLAS MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Acute leukemia; Hospital construction; Mold infections; Pediatric oncology

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; COTRIMOXAZOLE; FLUCONAZOLE; PENTAMADINE; UNCLASSIFIED DRUG; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASPERGILLOSIS; CANCER CHEMOTHERAPY; CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EXPOSURE; FEMALE; FUSARIOSIS; HEALTHCARE ASSOCIATED ENVIRONMENTAL MOLD INFECTION; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL BUILDING; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INVASIVE CANDIDIASIS; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PNEUMOCYSTOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDALLESCHERIASIS; RETROSPECTIVE STUDY; SYSTEMIC MYCOSIS;

EID: 84890889768     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24685     Document Type: Article

References (36)

1. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355:1572-1582.
2. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26:781-803.
3. Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 1998; 37:173-180.
4. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86:668-672.
5. Walsh TJ, Rubin M, Hathorn J, et al. Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study. Arch Intern Med 1991; 151:765-770.
6. Pizzo PA, Robichaud KJ, Wesley R, et al. Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine 1982; 61:153-165.
7. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003; 362:1828-1838.
8. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study. Haematologica 2006; 91:1068-1075.
9. Hamad M. Antifungal immunotherapy and immunomodulation: A double-hitter approach to deal with invasive fungal infections. Scand J Immunol 2008; 67:533-543.
10. Rosen GP, Nielsen K, Glenn S, et al. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol 2005; 27:135-140.
11. Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10:48-66.
12. Malani AN, Kauffman CA. Changing epidemiology of rare mould infections: Implications for therapy. Drugs 2007; 67:1803-1812.
13. Oren I, Haddad N, Finkelstein R, et al. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: Before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001; 66:257-262.
14. Streifel AJ, Lauer JL, Vesley D, et al. Aspergillus fumigatus and other thermotolerant fungi generated by hospital building demolition. Appl Environ Microbiol 1983; 46:375-378.
15. Pini G, Faggi E, Donato R, et al. Invasive pulmonary aspergillosis in neutropenic patients and the influence of hospital renovation. Mycoses 2008; 51:117-122.
16. Chang CC, Cheng AC, Devitt B, et al. Successful control of an outbreak of invasive aspergillosis in a regional haematology unit during hospital construction works. J Hosp Infect 2008; 69:33-38.
17. Sarubbi FA Jr, Kopf HB, Wilson MB, et al. Increased recovery of Aspergillus flavus from respiratory specimens during hospital construction. Am Rev Respir Dis 1982; 125:33-38.
18. Cheng SM, Streifel AJ. Infection control considerations during construction activities: Land excavation and demolition. Am J Infect Control 2001; 29:321-328.
19. Weber DJ, Peppercorn A, Miller MB, et al. Preventing healthcare-associated Aspergillus infections: Review of recent CDC/HICPAC recommendations. Med Mycol 2009; 47:S199-S209.
20. Sehulster L, Chinn RY. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003; 52:1-42.
21. Siegel JD, Rhinehart E, Jackson M, et al. Guideline for isolation precautions: Preventing transmission of infectious agents in health care settings. Am J Infect Control 2007; 35:S65-S164.
22. Vehreschild JJ, Böhme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007; 55:445-449.
23. Hughes WT, Armstrong D, Bodey GP, et al. guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-751.
24. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-1821.
25. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 1989; 84:1065-1073.
26. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989; 84:1074-1078.
27. Lehrnbecher T, Laws HJ, Boehm A, et al. Compliance with anti-infective preventive measures: A multicentre survey among paediatric oncology patients. Eur J Cancer 2008; 44:1861-1865.
28. Kidd F, Buttner C, Kressel AB. Construction: A model program for infection control compliance. Am J Infection Control 2007; 35:347-350.
29. Berger J, Willinger B, Diab-Elschahawi M, et al. Effectiveness of preventive measures for hemato-oncologic patients undergoing stem cell transplantation during a period of hospital construction. Am J Infect Control 2011; 39:746-751.
30. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary care cancer center in the era of aspergillosis-active antifungal therapy: A case control observational study of 27 recent cases. J Infect Dis 2005; 191:1350-1360.
31. Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 2005; 40:770-771.
32. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoetic stem-cell transplants. N Engl J Med 2004; 350:950-952.
33. Chamilos G, Kontoyiannis DP. Voriconazole-resistant disseminated Paecilomyces variotii infection in a neutropenic patient with leukemia on voriconazole prophylaxis. J Infect 2005; 51:225-228.
34. Seftel MD, Ho M, Pruthi D, et al. High rate of discordance between clinical and autopsy diagnoses in blood and marrow transplantation. Bone Marrow Transplant 2007; 40:1049-1053.
35. Partridge-Hinckley K, Liddell GM, Almyroudis NG, et al. Infection control measures to prevent invasive mould diseases in hematopoietic stem cell transplant recipients. Mycopathologia 2009; 168:329-337.
36. Haiduven D. Nosocomial aspergillosis and building construction. Med Mycol 2009; 47:S210-S216.